Genentech (Roche) Collaborates with BARDA to Launch Actemra Clinical Trial for Adult Patients with Severe COVID-19 Pneumonia

Genentech (Roche) Collaborates with BARDA to Launch Actemra Clinical Trial for Adult Patients with Severe COVID-19 Pneumonia

Genentech (Roche) plans a Phase III clinical trial to assess its marketed drug Actemra (tocilizumab) as a treatment for severe cases of COVID-19 in adults. In collaboration with the Biomedical Advanced Research and Development Authority (BARDA), the prominent company...
NIAID Sponsors Phase I Clinical Trial of mAb CIS43LS Targeting Malaria

NIAID Sponsors Phase I Clinical Trial of mAb CIS43LS Targeting Malaria

The National Institute of Allergy and Infectious Diseases (NIAID) has developed a monoclonal antibody (mAb) called mAb CIS43LS targeting malaria. They are now enrolling healthy adult volunteers in a Phase I clinical trial testing the safety and effectiveness of the...

Pin It on Pinterest